Monopar Therapeutics (NASDAQ:MNPR) Shares Down 5.7% – Should You Sell?

Posted by Stanley Muller on Sep 18th, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report)’s stock price traded down 5.7% on Friday . The stock traded as low as $97.00 and last traded at $96.8750. Approximately 52,451 shares were traded during trading, a decline of 75% from the average session volume of 212,361 shares. The stock had previously closed at $102.70.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Finally, UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.08.

View Our Latest Report on MNPR

Monopar Therapeutics Trading Down 5.6%

The firm has a 50-day moving average of $111.93 and a 200 day moving average of $80.60. The company has a market cap of $650.55 million, a P/E ratio of -44.64 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, equities analysts predict that Monopar Therapeutics Inc. will post -2.94 EPS for the current year.

Insiders Place Their Bets

In other news, Director Kim R. Tsuchimoto sold 4,090 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director owned 7,396 shares of the company’s stock, valued at $823,840.44. This represents a 35.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the transaction, the director owned 23,751 shares in the company, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MNPR. Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics in the 4th quarter valued at $86,000. Your Advocates Ltd. LLP acquired a new position in Monopar Therapeutics during the first quarter worth $183,000. The Manufacturers Life Insurance Company bought a new position in shares of Monopar Therapeutics in the first quarter valued at $250,000. Sei Investments Co. lifted its stake in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Monopar Therapeutics during the fourth quarter valued at about $654,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.